Candidate composite biomarker to inform drug treatments for diabetic kidney disease

INTRODUCTION: Current guidelines recommend renin angiotensin system inhibitors (RASi) as key components of treatment of diabetic kidney disease (DKD). Additional options include sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP1a), and mineralocortico...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Roger D., Abebe, Seyum, Distefano, Veronica, Mayer, Gert, Poli, Irene, Silvestri, Claudio, Slanzi, Debora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646536/
https://www.ncbi.nlm.nih.gov/pubmed/38020124
http://dx.doi.org/10.3389/fmed.2023.1271407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646536/
https://www.ncbi.nlm.nih.gov/pubmed/38020124
http://dx.doi.org/10.3389/fmed.2023.1271407

Ejemplares similares